Jon Mcclelland Lockard

Array ( [id] => 11962160 [patent_doc_number] => 20170266313 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-21 [patent_title] => 'METHODS OF DELIVERING DLL3 ANTIBODY DRUG CONJUGATES' [patent_app_type] => utility [patent_app_number] => 15/608991 [patent_app_country] => US [patent_app_date] => 2017-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 55 [patent_figures_cnt] => 55 [patent_no_of_words] => 72449 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15608991 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11962162 [patent_doc_number] => 20170266315 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-21 [patent_title] => 'ANTI-DLL3 ANTIBODY DRUG CONJUGATES FOR TREATING CANCER' [patent_app_type] => utility [patent_app_number] => 15/608996 [patent_app_country] => US [patent_app_date] => 2017-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 55 [patent_figures_cnt] => 55 [patent_no_of_words] => 72451 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15608996 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11901097 [patent_doc_number] => 09770518 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2017-09-26 [patent_title] => 'Anti-DLL3 antibody drug conjugates' [patent_app_type] => utility [patent_app_number] => 15/608988 [patent_app_country] => US [patent_app_date] => 2017-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 54 [patent_figures_cnt] => 65 [patent_no_of_words] => 72449 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15608988 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11894121 [patent_doc_number] => 09764042 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2017-09-19 [patent_title] => 'Methods of making DLL3 antibody drug conjugates' [patent_app_type] => utility [patent_app_number] => 15/608995 [patent_app_country] => US [patent_app_date] => 2017-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 54 [patent_figures_cnt] => 65 [patent_no_of_words] => 72448 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15608995 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17406049 [patent_doc_number] => 11246909 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-15 [patent_title] => Neuregulin based methods for treating heart failure [patent_app_type] => utility [patent_app_number] => 15/601856 [patent_app_country] => US [patent_app_date] => 2017-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9975 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15601856 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11954717 [patent_doc_number] => 20170258868 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-14 [patent_title] => 'Peptides for Inhibiting Angiogenesis' [patent_app_type] => utility [patent_app_number] => 15/602096 [patent_app_country] => US [patent_app_date] => 2017-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 13369 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15602096 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16009375 [patent_doc_number] => 20200179530 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => TARGETED DELIVERY OF THERAPEUTIC AGENTS AND IMAGING REAGENTS TO PANCREATIC CANCER CELLS [patent_app_type] => utility [patent_app_number] => 16/302543 [patent_app_country] => US [patent_app_date] => 2017-05-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8437 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16302543 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19210730 [patent_doc_number] => 11999778 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-04 [patent_title] => VH4 antibodies and compositions comprising the same [patent_app_type] => utility [patent_app_number] => 16/301187 [patent_app_country] => US [patent_app_date] => 2017-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 148 [patent_figures_cnt] => 157 [patent_no_of_words] => 24844 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16301187 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11936475 [patent_doc_number] => 20170240625 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-24 [patent_title] => 'Antagonist Antibodies Directed Against Calcitonin Gene- Related Peptide' [patent_app_type] => utility [patent_app_number] => 15/588512 [patent_app_country] => US [patent_app_date] => 2017-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 39145 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15588512 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11936474 [patent_doc_number] => 20170240624 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-24 [patent_title] => 'Antagonist Antibodies Directed Against Calcitonin Gene- Related Peptide' [patent_app_type] => utility [patent_app_number] => 15/588490 [patent_app_country] => US [patent_app_date] => 2017-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 39078 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15588490 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11936473 [patent_doc_number] => 20170240623 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-24 [patent_title] => 'Antagonist Antibodies Directed Against Calcitonin Gene- Related Peptide' [patent_app_type] => utility [patent_app_number] => 15/588461 [patent_app_country] => US [patent_app_date] => 2017-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 39075 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15588461 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11936472 [patent_doc_number] => 20170240622 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-24 [patent_title] => 'Antagonist Antibodies Directed Against Calcitonin Gene- Related Peptide' [patent_app_type] => utility [patent_app_number] => 15/588432 [patent_app_country] => US [patent_app_date] => 2017-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 39078 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15588432 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12283264 [patent_doc_number] => 09931402 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-04-03 [patent_title] => Compositions for the treatment of solid tumors [patent_app_type] => utility [patent_app_number] => 15/586727 [patent_app_country] => US [patent_app_date] => 2017-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 40 [patent_figures_cnt] => 10 [patent_no_of_words] => 11260 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15586727 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11936462 [patent_doc_number] => 20170240611 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-24 [patent_title] => 'Modulation of the VPS10p-Domain Receptor Family for the Treatment of Mental and Behavioural Disorders' [patent_app_type] => utility [patent_app_number] => 15/584972 [patent_app_country] => US [patent_app_date] => 2017-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 41912 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15584972 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18233214 [patent_doc_number] => 11597763 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-03-07 [patent_title] => Anti-Kv1.3 antibodies, and methods of production and use thereof [patent_app_type] => utility [patent_app_number] => 16/098670 [patent_app_country] => US [patent_app_date] => 2017-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 27 [patent_no_of_words] => 20568 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16098670 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15008529 [patent_doc_number] => 10450380 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-10-22 [patent_title] => Polypeptide immunogen for generating an antibody to non-functional P2X7 receptor [patent_app_type] => utility [patent_app_number] => 15/498301 [patent_app_country] => US [patent_app_date] => 2017-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9754 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15498301 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14345461 [patent_doc_number] => 20190154703 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-23 [patent_title] => Marker for Prognosis of a Clinical Outcome of an Autologous Intervertebral Disc Cell Transplantation, for Progress Assessment/Progress Monitoring of an Autologous Intervertebral Disc Cell Transplantation, for Assessing the Quality of Intervertebral Disc Cells, for Assessing the Quality of an Implant and/or Medication for Novel Therapies (ATMP) for the Treatment of an Intervertebral Disc Defect, and for Diagnosis of an Intervertebral and/or Spinal Column Defect [patent_app_type] => utility [patent_app_number] => 16/097598 [patent_app_country] => US [patent_app_date] => 2017-04-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11252 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16097598 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12975835 [patent_doc_number] => 20170340695 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-30 [patent_title] => METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT NEUROPATHY [patent_app_type] => utility [patent_app_number] => 15/488697 [patent_app_country] => US [patent_app_date] => 2017-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14299 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15488697 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12138243 [patent_doc_number] => 20180016326 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-18 [patent_title] => 'ANTIBODIES THAT BIND PEPTIDOGLYCAN RECOGNITION PROTEIN 1' [patent_app_type] => utility [patent_app_number] => 15/483390 [patent_app_country] => US [patent_app_date] => 2017-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 26088 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15483390 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11993988 [patent_doc_number] => 20170298143 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-19 [patent_title] => 'RSPO BINDING AGENTS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/480081 [patent_app_country] => US [patent_app_date] => 2017-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 52176 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15480081 [rel_patent_id] =>[rel_patent_doc_number] =>)